Peverelli L, De Rosa A, Domina E, Ciscato P, Sita G, Velardo D, Comi G P
ASST Lodi, Ospedale Maggiore di Lodi, Neurology Unit, Lodi, Italy.
Neuromuscular and Rare Diseases Unit, Department of Neuroscience, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milano, Italy.
J Neuromuscul Dis. 2020;7(4):511-514. doi: 10.3233/JND-200504.
Immune-related adverse events (irAE) during the administration of immune-checkpoint inhibitors (ICIs) become more evident due to the increased use of these therapies. To remind the importance of early recognition of this phenomenon, we report a paradigmatic case characterized by severe systemic inflammatory myopathy and severe cardiac involvement that abruptly precipitated in an untoward ending after one single dose of Pembrolizumab.
由于免疫检查点抑制剂（ICIs）使用的增加，其给药期间的免疫相关不良事件（irAE）变得更加明显。为提醒早期认识这一现象的重要性，我们报告了一例典型病例，其特征为严重的全身性炎性肌病和严重的心脏受累，在单次使用帕博利珠单抗后突然出现不良结局。
